Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy

Journal of Medical Virology

Volumn 83, Issue 6, 2011, Pages 1048-1057

  Azakami, Takahiro ^a,b,c   Hayes, C Nelson ^a,b,c   Sezaki, Hitomi ^d   Kobayashi, Mariko ^d   Akuta, Norio ^d   Suzuki, Fumitaka ^d   Kumada, Hiromitsu ^d   Abe, Hiromi ^a,b,c   Miki, Daiki ^a,b,c   Tsuge, Masataka ^a,b,c   Imamura, Michio ^a,b,c   Kawakami, Yoshiiku ^a,b,c   Takahashi, Shoichi ^a,b,c   Ochi, Hidenori ^a,b,c   Nakamura, Yusuke ^e   Kamatani, Naoyuki ^a   Chayama, Kazuaki ^a,b,c  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anemia; Dose reduction; Inosine triphosphate pyrophosphatase; Peg interferon; Single nucleotide polymorphism

Indexed keywords

HEMOGLOBIN; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; GENE; GENOTYPE; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INOSINE TRIPHOSPHATE PYROPHOSPHATASE GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS CORE; VIRUS DETECTION;

AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS;

EID: 79954585482     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22069     Document Type: Article

References (27)

1. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380.
2. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Arase Y, Ikeda K, Kumada H. 2006. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 78:83-90.
3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410.
4. Alter MJ. 1995. Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5-14.
5. Chevaliez S, Pawlotsky JM. 2007. Hepatitis C virus: Virology, diagnosis and management of antiviral therapy. World J Gastroenterol 13:2461-2466.
6. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial A, Solero P, Corrocher R. 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 31:997-1004.
7. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis - diagnosis, grading and staging. Hepatology 19:1513-1520.
8. Dienstag JL, McHutchison JG. 2006. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130:231-264; quiz 214-237.
9. Dieterich D, Wasserman R, Bräu N, Hassanein T, Bini E, Bowers P, Sulkowski M. 2003. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 98:2491-2499.
10. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995a. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b-Sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. J Clin Invest 96:224-230.
11. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995b. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230.
12. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81.
13. Fellay J, Thompson A, Ge D, Gumbs C, Urban T, Shianna K, Little L, Qiu P, Bertelsen A, Watson M, Warner A, Muir A, Brass C, Albrecht J, Sulkowski M, McHutchison J, Goldstein D. 2010. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408.
14. Ge DL, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
15. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
16. Hung CH, Lee CM, Lu SN, Wang JH, Chen CH, Hu TH, Kee KM, Chang KC, Tseng PL, Yen YH, Changchien CS. 2006. Anemia associated with antiviral therapy in chronic hepatitis C: Incidence, risk factors, and impact on treatment response. Liver Int 26:1079-1086.
17. Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J. 2010. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 16:4400-4409.
18. McHutchison J, Manns M, Patel K, Poynard T, Lindsay K, Trepo C, Dienstag J, Lee W, Mak C, Garaud J, Albrecht J, IHIT Group. 2002. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069.
19. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes C, Kumada H, Nakamura Y, Chayama K. 2010. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-A genome-wide study of Japanese HCV virus patients. Gastroenterology 139:1190-1197.
20. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. 2001. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46:471-477.
21. Olivier M. 2003. A haplotype map of the human genome. Physiol Genomics 13:3-9.
22. Romero-Gómez M, Del Mar Viloria M, Andrade R, Salmerón J, Diago M, Fernández-Rodríguez C, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez M, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641.
23. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J, Hepatitis CS. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1174.
24. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402.
25. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
26. Thompson A, Fellay J, Patel K, Tillmann H, Naggie S, Ge D, Urban T, Shianna K, Muir A, Fried M, Afdhal N, Goldstein D, McHutchison J. 2010. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139:1181-1189.
27. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. 1996. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 24:1003-1009.